Fludarabine Phosphate

• A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas… Recruiting
  2024-514596-18-00 Phase I/II 5 countries Novartis Pharma AG
• Cumulative exposure to Fludarabine in patients undergoing reduced intensity allogeneic stem cell transplantation in Belgium Recruiting
  2023-503723-26-00 Phase IV 1 country Universitair Ziekenhuis Gent
• A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and Exposed to Lenalido… Recruiting
  2024-515279-37-00 Phase III 17 countries Celgene Corp.
• A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i… Recruiting
  2023-507613-10-01 Phase I (FiH) 2 countries Cabaletta Bio Inc.
• Ziftomenib in combination with chemotherapy for children with relapsed/refractory acute leukemia Recruiting
  2023-505262-28-00 Phase I (Other) 5 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
• Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refrac… Recruiting
  2024-520436-15-00 Phase I (FiH) 1 country Ospedale Pediatrico Bambino Gesu
• Preparation for bone marrow transplantation through the combined use of chemo and radiotherapy (Reduced intensity: with lower doses or diffe… Recruiting
  2024-514483-11-00 Phase II 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
• Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory… Recruiting
  2024-519168-42-00 Phase I (Other) 1 country Ospedale Pediatrico Bambino Gesu
• IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting
  2024-519790-19-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting
  2023-506400-99-00 Phase II 3 countries Vall D Hebron Institute Of Oncology
• Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Recruiting
  2024-515624-36-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting
  2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
• A clinical trial to learn about the effects of YTB323 in people with difficult to treat severe diffuse cutaneous systemic sclerosis (dcSSc) Recruiting
  2023-510380-34-00 Phase II 10 countries Novartis Pharma AG
• A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects with WAS. Recruiting
  2024-517792-20-00 Phase III 1 country Fondazione Telethon Ets
• A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in P… Recruiting
  2023-506307-26-00 Phase I (Other) 1 country Autolus Limited
• Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with re… Recruiting
  2023-508420-36-00 Phase I 1 country Ospedale Pediatrico Bambino Gesu'
• Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory… Recruiting
  2023-508355-39-00 Phase I (FiH) 1 country Ospedale Pediatrico Bambino Gesu'
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau… Recruiting
  2024-514544-90-00 Phase I/II 1 country Fundacion De Investigacion Biomedica De Salamanca
• TCRaß+CD19+ depleted haploidentical stem cell transplantation followed by immunotherapy in patients with relapsed/resistant high-risk neurob… Recruiting
  2024-519089-32-02 Phase II 1 country IRCCS Istituto Giannina Gaslini
• CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML) Recruiting
  2023-504999-25-00 Phase III 12 countries Prinses Maxima Centrum voor Kinderoncologie B.V.
• Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting
  2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
• A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells. Recruiting
  2024-516091-15-00 Phase II 1 country Nosokomeio Paidon I Agia Sofia
• Studying Conditioning Regimen In Pediatric Transplantation -AML Recruiting
  2023-505512-37-00 Phase III 6 countries Vaestra Goetalandsregionen
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting
  2023-510515-19-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus

Showing 25–48 of 75 trials